CCL2 and colorectal cancer: This study showed that atovaquone could inhibit the expression of the inflammatory factors IL1B, IL6, CCL20, CCL2, CXCL8, CXCL6, IL6ST, FAS, IL10 and IL1A and could effectively inhibit the expression of EMT-related biomarkers in colorectal cancer in vivo.